Hamilton Lane Advisors LLC Acquires Shares of 29,478 Scholar Rock Holding Co. (NASDAQ:SRRK)

Hamilton Lane Advisors LLC bought a new stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 29,478 shares of the company's stock, valued at approximately $1,274,000. Scholar Rock accounts for 1.2% of Hamilton Lane Advisors LLC's portfolio, making the stock its 11th biggest position.

Other institutional investors also recently bought and sold shares of the company. Clearbridge Investments LLC purchased a new position in shares of Scholar Rock in the second quarter valued at approximately $6,223,000. Fisher Asset Management LLC boosted its position in Scholar Rock by 593.6% in the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company's stock valued at $5,879,000 after buying an additional 628,186 shares during the period. Millennium Management LLC boosted its position in Scholar Rock by 159.2% in the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company's stock valued at $7,710,000 after buying an additional 568,512 shares during the period. Marshall Wace LLP grew its stake in shares of Scholar Rock by 1,051.3% in the second quarter. Marshall Wace LLP now owns 487,285 shares of the company's stock worth $4,059,000 after acquiring an additional 444,961 shares in the last quarter. Finally, FMR LLC raised its stake in shares of Scholar Rock by 3.1% in the third quarter. FMR LLC now owns 10,196,046 shares of the company's stock valued at $81,670,000 after acquiring an additional 308,813 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Stock Down 0.9 %

Shares of NASDAQ:SRRK traded down $0.42 during trading on Thursday, hitting $43.90. 1,323,816 shares of the company were exchanged, compared to its average volume of 1,021,802. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The firm's 50 day moving average price is $38.70 and its 200-day moving average price is $22.47. The stock has a market capitalization of $4.11 billion, a P/E ratio of -18.68 and a beta of 0.52. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.19.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright boosted their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Piper Sandler upped their target price on shares of Scholar Rock from $28.00 to $42.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the company an "overweight" rating in a report on Monday, October 14th. Wedbush reissued an "outperform" rating and issued a $47.00 price objective on shares of Scholar Rock in a research report on Thursday, January 9th. Finally, Truist Financial lifted their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $40.43.

Insider Activity at Scholar Rock

In related news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the transaction, the insider now owns 10,850,005 shares in the company, valued at $417,616,692.45. This trade represents a 3.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 19.20% of the stock is owned by corporate insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.